YATHARTH

Yatharth Hospital & Trauma Care Services share price & financials

Price
₹844
Market cap
₹8.2k Cr
Sector
Healthcare
Calls analysed
7
Latest concall · Q1 FY27 · call held 11 Aug 2026

Yatharth Hospital & Trauma Care Services Limited Q1 FY27

Revenue 3,927 million +51%EBITDA 917 million +39%Consolidated EBITDA Margin 23.3% PAT 454 million

What went well

  • Highest ever quarterly revenue of ₹3,927 million, up 51% YoY and 15% QoQ, demonstrating strong growth momentum.
  • EBITDA grew by 39% year-on-year, reflecting operational leverage and efficient integration of new assets.
  • Faridabad Sector 20 hospital achieved EBITDA breakeven in a record 9 months, significantly ahead of the 12-14 months target.

What to watch

  • PAT was severely impacted by increased depreciation and finance costs due to significant capacity additions and capex over the past 12 months.
  • Consolidated EBITDA margin of 23.3% is lower than the adjusted 28.1% (excluding newer hospitals) due to the drag from ramping up new assets like New Delhi and Faridabad Sector 20.
Read the full call →

What Yatharth Hospital & Trauma Care Services Limited does

Yatharth Hospital & Trauma Care Services operates a chain of multi- and super-speciality hospitals delivering emergency, primary and complex tertiary care across cardiac sciences, oncology, neurosciences, renal sciences (including transplant), orthopaedics and spine, gastro sciences, pulmonology and interventional radiology. Founded in 2008 with a single facility in Delhi NCR, it has grown into a hospital network concentrated in high-density NCR micro-markets (Noida, Greater Noida, Faridabad, Delhi, Gurugram) with an additional hospital in Jhansi-Orchha and a newly integrated facility in Agra. It earns revenue from a mix of cash/TPA (insurance) patients and government-empanelled schemes, and also treats international patients from Africa and the CIS region through medical-value-travel partnerships. Growth has come through both greenfield hospital builds and acquisitions of existing facilities.

Hospitals in network
9 (including 1 under construction)
Total bed capacity
2,800+ beds (2,555 operational)
Centres of Excellence
12
Core clinical specialities
Cardiac sciences, oncology, neurosciences, renal sciences (incl. transplant), orthopaedics & spine, gastro sciences, pulmonology & internal medicine, interventional radiology
Specialities offered at Noida hospital
30+
Share of beds in metro locations
80%
Founded 2008Headquarters Jasola District Centre, New Delhi Company website

Guidance record · Q1 FY27

what the last two calls moved 28 tracked 8 delivered 5 missed 15 open
  • Revenue Growth delivered said Q3 FY25 Promised: upwards of 30% YoY Q1 FY27: Promise pertains to FY26 and was successfully met. No new updates.
  • Cumulative CAPEX Timeline went quiet said Q1 FY26 Promised: Rs. 1,400 crores to Rs. 1,500 crores over the next three years Q1 FY27: No specific update was provided on the cumulative INR 1,500 crore capex plan or its 5-year timeline.
  • ARPOB Growth at risk said Q3 FY25 Promised: 10% yearly for at least three to four years Q1 FY27: Q1 FY27 group ARPOB grew 7% YoY. Management reiterated the 8-10% annual growth guidance, but current performance continues to lag the target range.

All 28 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 35.4%, net profit up 3.7% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue113 110 112 130 137 +21%158 +44%164 +46%176 +35%
EBITDA31 32 32 35 27 −13%37 +16%39 +22%40 +14%
Net profit20 22 22 27 21 +5%24 +9%24 +9%28 +4%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +21.1% 1Y

₹0.6k₹0.7k₹0.8k₹0.9k₹1.0kSept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q2 FY26 — 14 Nov 2025Q3 FY26 — 6 Feb 2026Q4 FY26 — 26 May 2026Q1 FY27 — 11 Aug 2026

1Y: ₹798.05 on 10 Sept 2025 → ₹966.3. High ₹1,001.9 (31 Aug 2026), low ₹550.8 (23 Jan 2026).

How the price took the results

close before → close after

Q1 FY27
−3.7%
11 Aug
Q4 FY26
−0.5%
26 May
Q3 FY26
−0.8%
6 Feb
Q2 FY26
+6.5%
14 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 7.5% a year over 3 years, FY23 to FY26. Operating margin narrowed to 23.4%.

Year endingFY23FY24FY25FY26
Revenue₹474 Cr₹420 Cr₹454 Cr₹589 Cr
Operating profit₹124 Cr₹117 Cr₹128 Cr₹138 Cr
Operating margin26.2%27.9%28.2%23.4%
Interest₹17 Cr₹4 Cr₹0 Cr₹5 Cr
Depreciation₹23 Cr₹13 Cr₹19 Cr₹30 Cr
Net profit₹63 Cr₹84 Cr₹87 Cr₹96 Cr
Net margin13.3%20.0%19.2%16.3%
Cash from operations₹26 Cr₹16 Cr₹89 Cr₹95 Cr
Free cash flow₹17 Cr₹-18 Cr₹-116 Cr₹-21 Cr
ROCE37.0%21.0%10.0%8.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹16 Cr₹66 Cr₹66 Cr₹86 Cr₹96 Cr₹96 Cr
Reserves₹53 Cr₹46 Cr₹111 Cr₹751 Cr₹1.6k Cr₹1.5k Cr
Borrowings₹103 Cr₹115 Cr₹117 Cr₹5 Cr₹26 Cr₹36 Cr
Other liabilities₹39 Cr₹59 Cr₹33 Cr₹36 Cr₹141 Cr₹286 Cr
Total liabilities₹211 Cr₹286 Cr₹326 Cr₹878 Cr₹1.9k Cr₹1.9k Cr
Fixed assets₹132 Cr₹122 Cr₹121 Cr₹133 Cr₹852 Cr₹393 Cr
Capital work in progress₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹110 Cr₹18 Cr
Investments₹34 Cr₹47 Cr₹47 Cr₹67 Cr₹21 Cr₹534 Cr
Other assets₹45 Cr₹117 Cr₹159 Cr₹679 Cr₹873 Cr₹996 Cr
Total assets₹211 Cr₹286 Cr₹326 Cr₹878 Cr₹1.9k Cr₹1.9k Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, the public added +7.24 pp while promoters trimmed −5.84 pp. The shareholder count grew 18% to 96,264.

Promoters
55.8%
FIIs
5.6%
DIIs
10.8%
Public
27.7%

Since Jun 2025

  • Public +7.24 pp
  • Promoters −5.84 pp
  • DIIs −2.68 pp

How it drifted, 12 quarters

Over this window promoters fell from 66.3% to 55.8% — −10.5 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 66.3%, FIIs 5.4%, DIIs 8.9%, Public 19.4%.Dec '23: Promoters 66.4%, FIIs 2.6%, DIIs 8.8%, Public 22.1%.Mar '24: Promoters 66.5%, FIIs 4.0%, DIIs 9.3%, Public 20.1%.Jun '24: Promoters 66.5%, FIIs 4.9%, DIIs 9.4%, Public 19.2%.Sep '24: Promoters 66.5%, FIIs 6.3%, DIIs 7.0%, Public 20.2%.Dec '24: Promoters 61.4%, FIIs 9.8%, DIIs 11.5%, Public 17.3%.Mar '25: Promoters 61.6%, FIIs 4.5%, DIIs 13.6%, Public 20.4%.Jun '25: Promoters 61.6%, FIIs 4.3%, DIIs 13.5%, Public 20.5%.Sep '25: Promoters 61.6%, FIIs 6.5%, DIIs 8.7%, Public 23.2%.Dec '25: Promoters 55.8%, FIIs 6.2%, DIIs 11.0%, Public 27.0%.Mar '26: Promoters 55.8%, FIIs 5.3%, DIIs 12.0%, Public 26.9%.Jun '26: Promoters 55.8%, FIIs 5.6%, DIIs 10.8%, Public 27.7%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Yatharth Hospital & Trauma Care Services Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Ajay Kumar Tyagi 30.59%unchanged
Kapil Kumar 12.62%unchanged
Manju Tyagi 11.96%unchanged
Kotak Mahindra Trustee Co Ltd A/C Kotak Multicap Fund Mutual fund5.00%+0.11 pp
Bandhan Small Cap Fund Mutual fund4.24%+0.15 pp
Jupiter India Fund Global fund house1.16%unchanged
Mukul Mahavir Agrawal 1.14%unchanged
Kedia Securities Private Limited 1.00%unchanged
Neena Tyagi 0.62%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

What the price assumes

Growth trap

To justify its price of ₹966, this stock must grow earnings at 49% every year for 7 years. Our analysis caps realistic growth at ~15%. At that growth it is worth ₹187 — downside of 81%.

Growth the price implies
48.9% a year
for 7 years, fading to 4%
It has actually compounded at
15.1% a year
net profit, FY23–FY26
The gap
0.3 pp
-81% downside if it only repeats history
Price today ₹966.3 Value at the reference growth ₹187.46

Change the assumptions yourself →

All earnings calls (7)

Read the Q1 FY27 call →

Learn to analyse Yatharth Hospital & Trauma Care Services Limited

Guides on how to read this kind of business and the numbers that matter.